Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Predicting PD-1 checkpoint inhibitor sensitivity in prostate cancer: potential molecular biomarkers

Emmanuel Antonarakis • 6 Mar 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer Checkpoint Inhibitors Pembrolizumab

Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. Dr Antonarakis discusses a recent publication by his group on the need for a new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer, highlighting three potential molecular biomarkers for PD-1 inhibitor response.

More from Emmanuel Antonarakis

3:56
PARP inhibitors: activity in BRCA1 versus BRCA2 altered mCRPC
Emmanuel Antonarakis • 12 Feb 2021
2:58
Characterization of PSA responses to bipolar androgen therapy in mCRPC
Emmanuel Antonarakis • 12 Feb 2021
1:46
Genomic and clinical features of SPOP mutations in prostate cancer
Emmanuel Antonarakis • 12 Feb 2021
3:18
KEYNOTE-199: an update on pembrolizumab for mCRPC
Emmanuel Antonarakis • 13 Feb 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals